Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

VX17-445-103 Trial Group

Research output: Contribution to journalArticlepeer-review

262 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences